

BEST AVAILABLE COPY

In the Claims:

Claims 1-59 (Cancelled)

60. (Previously Amended): An isolated polypeptide comprising a member selected from the group consisting of

- (a) the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4.

61. (Previously Amended): The isolated polypeptide of claim 60, wherein the polypeptide is according to (a).

62. (Previously Added): The isolated polypeptide of claim 60, wherein the polypeptide is according to (b).

63. (Previously Added): The isolated polypeptide of claim 60, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.

64. (Previously Added): The isolated polypeptide of claim 60, wherein the isolated polypeptide consists of SEQ ID NO:2 or SEQ ID NO:4.

65. (Previously Added): A fusion protein comprising the isolated polypeptide of Claim 60.

66. (Currently Amended): An immunogenic ~~immogenic~~ composition comprising the polypeptide of Claim 60 and a pharmaceutically acceptable carrier.

BEST AVAILABLE COPY

Serial No.: 09/700,293

Docket No.: BM45321

67. (Previously Amended): The immunogenic composition of Claim 66, wherein the immunogenic composition further comprises at least one other *Neisseria Meningitidis* antigen.
